New combo therapy shows promise for older AML patients
NCT ID NCT02835222
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests whether adding the drug selinexor to standard chemotherapy can help older adults with untreated acute myeloid leukemia (AML) live longer and achieve remission. About 57 participants will receive either standard chemo alone or chemo plus selinexor, followed by maintenance therapy. The goal is to see if the combination improves survival and reduces cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNTREATED ADULT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, 27157, United States
-
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Gene-Targeting drug boost chemo for older leukemia patients?
- Can a biomarker predict who responds to a new AML combo?
- Promising drug combo targets tough leukemia in early trial
- New chemo cocktail targets tough leukemias
- Engineered immune cells take aim at stubborn blood cancers
- New cocktail of 5 drugs targets tough leukemia